nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—MPO—urinary bladder cancer	0.541	1	CbGaD
Octreotide—MPO—Carboplatin—urinary bladder cancer	0.151	0.539	CbGbCtD
Octreotide—MPO—Cisplatin—urinary bladder cancer	0.129	0.461	CbGbCtD
Octreotide—SSTR1—prostate gland—urinary bladder cancer	0.00366	0.283	CbGeAlD
Octreotide—SSTR4—female reproductive system—urinary bladder cancer	0.0031	0.24	CbGeAlD
Octreotide—SSTR2—renal system—urinary bladder cancer	0.00212	0.164	CbGeAlD
Octreotide—SSTR1—female reproductive system—urinary bladder cancer	0.002	0.155	CbGeAlD
Octreotide—MPO—epithelium—urinary bladder cancer	0.000867	0.067	CbGeAlD
Octreotide—MPO—renal system—urinary bladder cancer	0.000804	0.0621	CbGeAlD
Octreotide—MPO—C-MYB transcription factor network—PTCRA—urinary bladder cancer	0.000425	0.0553	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—SLC19A1—urinary bladder cancer	0.000401	0.0522	CbGpPWpGaD
Octreotide—MPO—lymph node—urinary bladder cancer	0.000377	0.0291	CbGeAlD
Octreotide—MPO—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.000215	0.028	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—SOD2—urinary bladder cancer	0.000172	0.0224	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000166	0.0216	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—MTHFR—urinary bladder cancer	0.000152	0.0197	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—SOD2—urinary bladder cancer	0.00014	0.0182	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000136	0.0177	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—GPX1—urinary bladder cancer	0.000134	0.0174	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—MTHFR—urinary bladder cancer	0.000123	0.016	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—IL2—urinary bladder cancer	0.000116	0.0151	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000115	0.015	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000115	0.015	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000111	0.0145	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000106	0.0138	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	9.79e-05	0.0127	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	8.81e-05	0.0115	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—TNF—urinary bladder cancer	8.43e-05	0.011	CbGpPWpGaD
Octreotide—Pneumonia—Doxorubicin—urinary bladder cancer	8.26e-05	0.000522	CcSEcCtD
Octreotide—Gastrointestinal pain—Etoposide—urinary bladder cancer	8.26e-05	0.000522	CcSEcCtD
Octreotide—Pruritus—Fluorouracil—urinary bladder cancer	8.23e-05	0.00052	CcSEcCtD
Octreotide—SSTR4—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	8.22e-05	0.0107	CbGpPWpGaD
Octreotide—Drowsiness—Doxorubicin—urinary bladder cancer	8.22e-05	0.000519	CcSEcCtD
Octreotide—Visual impairment—Methotrexate—urinary bladder cancer	8.21e-05	0.000519	CcSEcCtD
Octreotide—Hypersensitivity—Cisplatin—urinary bladder cancer	8.13e-05	0.000514	CcSEcCtD
Octreotide—Bradycardia—Epirubicin—urinary bladder cancer	8.12e-05	0.000513	CcSEcCtD
Octreotide—Diarrhoea—Gemcitabine—urinary bladder cancer	8.1e-05	0.000512	CcSEcCtD
Octreotide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	8.05e-05	0.000509	CcSEcCtD
Octreotide—Urticaria—Etoposide—urinary bladder cancer	8.03e-05	0.000507	CcSEcCtD
Octreotide—Jaundice—Doxorubicin—urinary bladder cancer	8.01e-05	0.000506	CcSEcCtD
Octreotide—Rhinitis—Epirubicin—urinary bladder cancer	7.99e-05	0.000505	CcSEcCtD
Octreotide—Body temperature increased—Etoposide—urinary bladder cancer	7.99e-05	0.000505	CcSEcCtD
Octreotide—Abdominal pain—Etoposide—urinary bladder cancer	7.99e-05	0.000505	CcSEcCtD
Octreotide—Conjunctivitis—Doxorubicin—urinary bladder cancer	7.99e-05	0.000505	CcSEcCtD
Octreotide—Urinary tract infection—Doxorubicin—urinary bladder cancer	7.99e-05	0.000505	CcSEcCtD
Octreotide—Hepatitis—Epirubicin—urinary bladder cancer	7.97e-05	0.000504	CcSEcCtD
Octreotide—Diarrhoea—Fluorouracil—urinary bladder cancer	7.96e-05	0.000503	CcSEcCtD
Octreotide—Tinnitus—Methotrexate—urinary bladder cancer	7.94e-05	0.000502	CcSEcCtD
Octreotide—Hypoaesthesia—Epirubicin—urinary bladder cancer	7.93e-05	0.000501	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—CREBBP—urinary bladder cancer	7.92e-05	0.0103	CbGpPWpGaD
Octreotide—Asthenia—Cisplatin—urinary bladder cancer	7.91e-05	0.0005	CcSEcCtD
Octreotide—Pharyngitis—Epirubicin—urinary bladder cancer	7.91e-05	0.0005	CcSEcCtD
Octreotide—Cardiac disorder—Methotrexate—urinary bladder cancer	7.91e-05	0.0005	CcSEcCtD
Octreotide—Oedema peripheral—Epirubicin—urinary bladder cancer	7.85e-05	0.000496	CcSEcCtD
Octreotide—Haematuria—Doxorubicin—urinary bladder cancer	7.83e-05	0.000495	CcSEcCtD
Octreotide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	7.77e-05	0.000491	CcSEcCtD
Octreotide—Epistaxis—Doxorubicin—urinary bladder cancer	7.75e-05	0.00049	CcSEcCtD
Octreotide—Sinusitis—Doxorubicin—urinary bladder cancer	7.71e-05	0.000487	CcSEcCtD
Octreotide—Immune system disorder—Methotrexate—urinary bladder cancer	7.69e-05	0.000486	CcSEcCtD
Octreotide—Dizziness—Fluorouracil—urinary bladder cancer	7.69e-05	0.000486	CcSEcCtD
Octreotide—Visual impairment—Epirubicin—urinary bladder cancer	7.68e-05	0.000486	CcSEcCtD
Octreotide—Diarrhoea—Cisplatin—urinary bladder cancer	7.55e-05	0.000477	CcSEcCtD
Octreotide—Alopecia—Methotrexate—urinary bladder cancer	7.53e-05	0.000476	CcSEcCtD
Octreotide—Vomiting—Gemcitabine—urinary bladder cancer	7.52e-05	0.000476	CcSEcCtD
Octreotide—Bradycardia—Doxorubicin—urinary bladder cancer	7.51e-05	0.000475	CcSEcCtD
Octreotide—Mental disorder—Methotrexate—urinary bladder cancer	7.46e-05	0.000472	CcSEcCtD
Octreotide—Rash—Gemcitabine—urinary bladder cancer	7.46e-05	0.000472	CcSEcCtD
Octreotide—Dermatitis—Gemcitabine—urinary bladder cancer	7.45e-05	0.000471	CcSEcCtD
Octreotide—Hypersensitivity—Etoposide—urinary bladder cancer	7.44e-05	0.000471	CcSEcCtD
Octreotide—Tinnitus—Epirubicin—urinary bladder cancer	7.43e-05	0.00047	CcSEcCtD
Octreotide—Malnutrition—Methotrexate—urinary bladder cancer	7.42e-05	0.000469	CcSEcCtD
Octreotide—Erythema—Methotrexate—urinary bladder cancer	7.42e-05	0.000469	CcSEcCtD
Octreotide—Headache—Gemcitabine—urinary bladder cancer	7.41e-05	0.000469	CcSEcCtD
Octreotide—Flushing—Epirubicin—urinary bladder cancer	7.4e-05	0.000468	CcSEcCtD
Octreotide—Cardiac disorder—Epirubicin—urinary bladder cancer	7.4e-05	0.000468	CcSEcCtD
Octreotide—Vomiting—Fluorouracil—urinary bladder cancer	7.4e-05	0.000468	CcSEcCtD
Octreotide—Rhinitis—Doxorubicin—urinary bladder cancer	7.39e-05	0.000467	CcSEcCtD
Octreotide—Hepatitis—Doxorubicin—urinary bladder cancer	7.38e-05	0.000466	CcSEcCtD
Octreotide—Hypoaesthesia—Doxorubicin—urinary bladder cancer	7.34e-05	0.000464	CcSEcCtD
Octreotide—Rash—Fluorouracil—urinary bladder cancer	7.34e-05	0.000464	CcSEcCtD
Octreotide—Dermatitis—Fluorouracil—urinary bladder cancer	7.33e-05	0.000463	CcSEcCtD
Octreotide—Pharyngitis—Doxorubicin—urinary bladder cancer	7.32e-05	0.000463	CcSEcCtD
Octreotide—Headache—Fluorouracil—urinary bladder cancer	7.29e-05	0.000461	CcSEcCtD
Octreotide—MPO—Folate Metabolism—IL2—urinary bladder cancer	7.29e-05	0.00949	CbGpPWpGaD
Octreotide—Oedema peripheral—Doxorubicin—urinary bladder cancer	7.27e-05	0.000459	CcSEcCtD
Octreotide—Asthenia—Etoposide—urinary bladder cancer	7.25e-05	0.000458	CcSEcCtD
Octreotide—SSTR2—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	7.21e-05	0.00938	CbGpPWpGaD
Octreotide—Immune system disorder—Epirubicin—urinary bladder cancer	7.2e-05	0.000455	CcSEcCtD
Octreotide—Back pain—Methotrexate—urinary bladder cancer	7.17e-05	0.000453	CcSEcCtD
Octreotide—Pruritus—Etoposide—urinary bladder cancer	7.15e-05	0.000452	CcSEcCtD
Octreotide—Arrhythmia—Epirubicin—urinary bladder cancer	7.12e-05	0.00045	CcSEcCtD
Octreotide—Visual impairment—Doxorubicin—urinary bladder cancer	7.11e-05	0.000449	CcSEcCtD
Octreotide—Alopecia—Epirubicin—urinary bladder cancer	7.04e-05	0.000445	CcSEcCtD
Octreotide—Nausea—Gemcitabine—urinary bladder cancer	7.03e-05	0.000444	CcSEcCtD
Octreotide—Vomiting—Cisplatin—urinary bladder cancer	7.01e-05	0.000443	CcSEcCtD
Octreotide—SSTR1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	6.99e-05	0.0091	CbGpPWpGaD
Octreotide—Vision blurred—Methotrexate—urinary bladder cancer	6.99e-05	0.000442	CcSEcCtD
Octreotide—Mental disorder—Epirubicin—urinary bladder cancer	6.98e-05	0.000442	CcSEcCtD
Octreotide—Rash—Cisplatin—urinary bladder cancer	6.95e-05	0.00044	CcSEcCtD
Octreotide—Dermatitis—Cisplatin—urinary bladder cancer	6.95e-05	0.000439	CcSEcCtD
Octreotide—Malnutrition—Epirubicin—urinary bladder cancer	6.94e-05	0.000439	CcSEcCtD
Octreotide—Erythema—Epirubicin—urinary bladder cancer	6.94e-05	0.000439	CcSEcCtD
Octreotide—SSTR4—G alpha (i) signalling events—CXCL8—urinary bladder cancer	6.94e-05	0.00903	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	6.93e-05	0.00903	CbGpPWpGaD
Octreotide—Diarrhoea—Etoposide—urinary bladder cancer	6.91e-05	0.000437	CcSEcCtD
Octreotide—Nausea—Fluorouracil—urinary bladder cancer	6.91e-05	0.000437	CcSEcCtD
Octreotide—Ill-defined disorder—Methotrexate—urinary bladder cancer	6.88e-05	0.000435	CcSEcCtD
Octreotide—Tinnitus—Doxorubicin—urinary bladder cancer	6.88e-05	0.000435	CcSEcCtD
Octreotide—Anaemia—Methotrexate—urinary bladder cancer	6.85e-05	0.000433	CcSEcCtD
Octreotide—Cardiac disorder—Doxorubicin—urinary bladder cancer	6.85e-05	0.000433	CcSEcCtD
Octreotide—Flushing—Doxorubicin—urinary bladder cancer	6.85e-05	0.000433	CcSEcCtD
Octreotide—Flatulence—Epirubicin—urinary bladder cancer	6.84e-05	0.000432	CcSEcCtD
Octreotide—Tension—Epirubicin—urinary bladder cancer	6.81e-05	0.000431	CcSEcCtD
Octreotide—Nervousness—Epirubicin—urinary bladder cancer	6.74e-05	0.000426	CcSEcCtD
Octreotide—Back pain—Epirubicin—urinary bladder cancer	6.71e-05	0.000424	CcSEcCtD
Octreotide—Malaise—Methotrexate—urinary bladder cancer	6.69e-05	0.000423	CcSEcCtD
Octreotide—Dizziness—Etoposide—urinary bladder cancer	6.68e-05	0.000422	CcSEcCtD
Octreotide—Muscle spasms—Epirubicin—urinary bladder cancer	6.67e-05	0.000422	CcSEcCtD
Octreotide—Immune system disorder—Doxorubicin—urinary bladder cancer	6.66e-05	0.000421	CcSEcCtD
Octreotide—Vertigo—Methotrexate—urinary bladder cancer	6.66e-05	0.000421	CcSEcCtD
Octreotide—Arrhythmia—Doxorubicin—urinary bladder cancer	6.59e-05	0.000417	CcSEcCtD
Octreotide—Nausea—Cisplatin—urinary bladder cancer	6.55e-05	0.000414	CcSEcCtD
Octreotide—Vision blurred—Epirubicin—urinary bladder cancer	6.54e-05	0.000413	CcSEcCtD
Octreotide—MPO—Vitamin B12 Metabolism—TNF—urinary bladder cancer	6.52e-05	0.00849	CbGpPWpGaD
Octreotide—Alopecia—Doxorubicin—urinary bladder cancer	6.52e-05	0.000412	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—PTGS2—urinary bladder cancer	6.48e-05	0.00844	CbGpPWpGaD
Octreotide—Cough—Methotrexate—urinary bladder cancer	6.47e-05	0.000409	CcSEcCtD
Octreotide—Mental disorder—Doxorubicin—urinary bladder cancer	6.46e-05	0.000409	CcSEcCtD
Octreotide—Ill-defined disorder—Epirubicin—urinary bladder cancer	6.44e-05	0.000407	CcSEcCtD
Octreotide—Convulsion—Methotrexate—urinary bladder cancer	6.42e-05	0.000406	CcSEcCtD
Octreotide—Vomiting—Etoposide—urinary bladder cancer	6.42e-05	0.000406	CcSEcCtD
Octreotide—Malnutrition—Doxorubicin—urinary bladder cancer	6.42e-05	0.000406	CcSEcCtD
Octreotide—Erythema—Doxorubicin—urinary bladder cancer	6.42e-05	0.000406	CcSEcCtD
Octreotide—Anaemia—Epirubicin—urinary bladder cancer	6.41e-05	0.000405	CcSEcCtD
Octreotide—Agitation—Epirubicin—urinary bladder cancer	6.38e-05	0.000403	CcSEcCtD
Octreotide—Rash—Etoposide—urinary bladder cancer	6.37e-05	0.000403	CcSEcCtD
Octreotide—Dermatitis—Etoposide—urinary bladder cancer	6.36e-05	0.000402	CcSEcCtD
Octreotide—Headache—Etoposide—urinary bladder cancer	6.33e-05	0.0004	CcSEcCtD
Octreotide—Flatulence—Doxorubicin—urinary bladder cancer	6.33e-05	0.0004	CcSEcCtD
Octreotide—Myalgia—Methotrexate—urinary bladder cancer	6.31e-05	0.000399	CcSEcCtD
Octreotide—Arthralgia—Methotrexate—urinary bladder cancer	6.31e-05	0.000399	CcSEcCtD
Octreotide—Chest pain—Methotrexate—urinary bladder cancer	6.31e-05	0.000399	CcSEcCtD
Octreotide—Tension—Doxorubicin—urinary bladder cancer	6.3e-05	0.000398	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	6.27e-05	0.000396	CcSEcCtD
Octreotide—Malaise—Epirubicin—urinary bladder cancer	6.26e-05	0.000396	CcSEcCtD
Octreotide—MPO—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	6.25e-05	0.00813	CbGpPWpGaD
Octreotide—Discomfort—Methotrexate—urinary bladder cancer	6.24e-05	0.000394	CcSEcCtD
Octreotide—Nervousness—Doxorubicin—urinary bladder cancer	6.24e-05	0.000394	CcSEcCtD
Octreotide—Vertigo—Epirubicin—urinary bladder cancer	6.23e-05	0.000394	CcSEcCtD
Octreotide—SSTR3—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	6.23e-05	0.00811	CbGpPWpGaD
Octreotide—Syncope—Epirubicin—urinary bladder cancer	6.22e-05	0.000393	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—HDAC4—urinary bladder cancer	6.22e-05	0.0081	CbGpPWpGaD
Octreotide—Back pain—Doxorubicin—urinary bladder cancer	6.21e-05	0.000393	CcSEcCtD
Octreotide—Muscle spasms—Doxorubicin—urinary bladder cancer	6.17e-05	0.00039	CcSEcCtD
Octreotide—Palpitations—Epirubicin—urinary bladder cancer	6.13e-05	0.000388	CcSEcCtD
Octreotide—Loss of consciousness—Epirubicin—urinary bladder cancer	6.1e-05	0.000386	CcSEcCtD
Octreotide—Cough—Epirubicin—urinary bladder cancer	6.06e-05	0.000383	CcSEcCtD
Octreotide—Anaphylactic shock—Methotrexate—urinary bladder cancer	6.05e-05	0.000383	CcSEcCtD
Octreotide—Vision blurred—Doxorubicin—urinary bladder cancer	6.05e-05	0.000383	CcSEcCtD
Octreotide—Convulsion—Epirubicin—urinary bladder cancer	6.01e-05	0.00038	CcSEcCtD
Octreotide—Infection—Methotrexate—urinary bladder cancer	6.01e-05	0.00038	CcSEcCtD
Octreotide—Nausea—Etoposide—urinary bladder cancer	6e-05	0.000379	CcSEcCtD
Octreotide—SSTR1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	6e-05	0.00781	CbGpPWpGaD
Octreotide—Hypertension—Epirubicin—urinary bladder cancer	5.99e-05	0.000379	CcSEcCtD
Octreotide—SSTR1—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	5.97e-05	0.00778	CbGpPWpGaD
Octreotide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	5.96e-05	0.000377	CcSEcCtD
Octreotide—Nervous system disorder—Methotrexate—urinary bladder cancer	5.93e-05	0.000375	CcSEcCtD
Octreotide—Anaemia—Doxorubicin—urinary bladder cancer	5.93e-05	0.000375	CcSEcCtD
Octreotide—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.93e-05	0.000375	CcSEcCtD
Octreotide—Myalgia—Epirubicin—urinary bladder cancer	5.91e-05	0.000374	CcSEcCtD
Octreotide—Chest pain—Epirubicin—urinary bladder cancer	5.91e-05	0.000374	CcSEcCtD
Octreotide—Arthralgia—Epirubicin—urinary bladder cancer	5.91e-05	0.000374	CcSEcCtD
Octreotide—Agitation—Doxorubicin—urinary bladder cancer	5.9e-05	0.000373	CcSEcCtD
Octreotide—Anxiety—Epirubicin—urinary bladder cancer	5.89e-05	0.000372	CcSEcCtD
Octreotide—Skin disorder—Methotrexate—urinary bladder cancer	5.88e-05	0.000372	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	5.87e-05	0.000371	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—CCND1—urinary bladder cancer	5.86e-05	0.00763	CbGpPWpGaD
Octreotide—Hyperhidrosis—Methotrexate—urinary bladder cancer	5.85e-05	0.00037	CcSEcCtD
Octreotide—Discomfort—Epirubicin—urinary bladder cancer	5.84e-05	0.000369	CcSEcCtD
Octreotide—Malaise—Doxorubicin—urinary bladder cancer	5.79e-05	0.000366	CcSEcCtD
Octreotide—Dry mouth—Epirubicin—urinary bladder cancer	5.78e-05	0.000365	CcSEcCtD
Octreotide—Vertigo—Doxorubicin—urinary bladder cancer	5.77e-05	0.000365	CcSEcCtD
Octreotide—Anorexia—Methotrexate—urinary bladder cancer	5.77e-05	0.000365	CcSEcCtD
Octreotide—Syncope—Doxorubicin—urinary bladder cancer	5.76e-05	0.000364	CcSEcCtD
Octreotide—SSTR2—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	5.72e-05	0.00745	CbGpPWpGaD
Octreotide—Palpitations—Doxorubicin—urinary bladder cancer	5.67e-05	0.000359	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	5.67e-05	0.00738	CbGpPWpGaD
Octreotide—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.66e-05	0.000358	CcSEcCtD
Octreotide—Oedema—Epirubicin—urinary bladder cancer	5.66e-05	0.000358	CcSEcCtD
Octreotide—Loss of consciousness—Doxorubicin—urinary bladder cancer	5.64e-05	0.000357	CcSEcCtD
Octreotide—Infection—Epirubicin—urinary bladder cancer	5.63e-05	0.000356	CcSEcCtD
Octreotide—Cough—Doxorubicin—urinary bladder cancer	5.6e-05	0.000354	CcSEcCtD
Octreotide—Shock—Epirubicin—urinary bladder cancer	5.57e-05	0.000352	CcSEcCtD
Octreotide—Convulsion—Doxorubicin—urinary bladder cancer	5.56e-05	0.000352	CcSEcCtD
Octreotide—Nervous system disorder—Epirubicin—urinary bladder cancer	5.55e-05	0.000351	CcSEcCtD
Octreotide—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.55e-05	0.000351	CcSEcCtD
Octreotide—Hypertension—Doxorubicin—urinary bladder cancer	5.54e-05	0.00035	CcSEcCtD
Octreotide—Tachycardia—Epirubicin—urinary bladder cancer	5.53e-05	0.000349	CcSEcCtD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	5.51e-05	0.00718	CbGpPWpGaD
Octreotide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.51e-05	0.000349	CcSEcCtD
Octreotide—Skin disorder—Epirubicin—urinary bladder cancer	5.5e-05	0.000348	CcSEcCtD
Octreotide—Hyperhidrosis—Epirubicin—urinary bladder cancer	5.48e-05	0.000346	CcSEcCtD
Octreotide—Insomnia—Methotrexate—urinary bladder cancer	5.47e-05	0.000346	CcSEcCtD
Octreotide—Arthralgia—Doxorubicin—urinary bladder cancer	5.47e-05	0.000346	CcSEcCtD
Octreotide—Chest pain—Doxorubicin—urinary bladder cancer	5.47e-05	0.000346	CcSEcCtD
Octreotide—Myalgia—Doxorubicin—urinary bladder cancer	5.47e-05	0.000346	CcSEcCtD
Octreotide—Anxiety—Doxorubicin—urinary bladder cancer	5.45e-05	0.000344	CcSEcCtD
Octreotide—Paraesthesia—Methotrexate—urinary bladder cancer	5.43e-05	0.000344	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	5.43e-05	0.000343	CcSEcCtD
Octreotide—Discomfort—Doxorubicin—urinary bladder cancer	5.4e-05	0.000341	CcSEcCtD
Octreotide—Anorexia—Epirubicin—urinary bladder cancer	5.4e-05	0.000341	CcSEcCtD
Octreotide—Dyspnoea—Methotrexate—urinary bladder cancer	5.4e-05	0.000341	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—EP300—urinary bladder cancer	5.39e-05	0.00702	CbGpPWpGaD
Octreotide—Somnolence—Methotrexate—urinary bladder cancer	5.38e-05	0.00034	CcSEcCtD
Octreotide—Dry mouth—Doxorubicin—urinary bladder cancer	5.35e-05	0.000338	CcSEcCtD
Octreotide—Dyspepsia—Methotrexate—urinary bladder cancer	5.33e-05	0.000337	CcSEcCtD
Octreotide—MPO—Folate Metabolism—TNF—urinary bladder cancer	5.31e-05	0.00691	CbGpPWpGaD
Octreotide—SSTR5—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	5.3e-05	0.0069	CbGpPWpGaD
Octreotide—Decreased appetite—Methotrexate—urinary bladder cancer	5.26e-05	0.000333	CcSEcCtD
Octreotide—SSTR3—G alpha (i) signalling events—CXCL8—urinary bladder cancer	5.26e-05	0.00684	CbGpPWpGaD
Octreotide—Oedema—Doxorubicin—urinary bladder cancer	5.24e-05	0.000331	CcSEcCtD
Octreotide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.24e-05	0.000331	CcSEcCtD
Octreotide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.22e-05	0.00033	CcSEcCtD
Octreotide—Fatigue—Methotrexate—urinary bladder cancer	5.22e-05	0.00033	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—GLI1—urinary bladder cancer	5.21e-05	0.00679	CbGpPWpGaD
Octreotide—Infection—Doxorubicin—urinary bladder cancer	5.21e-05	0.000329	CcSEcCtD
Octreotide—Pain—Methotrexate—urinary bladder cancer	5.18e-05	0.000327	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.16e-05	0.000326	CcSEcCtD
Octreotide—Shock—Doxorubicin—urinary bladder cancer	5.16e-05	0.000326	CcSEcCtD
Octreotide—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.14e-05	0.000325	CcSEcCtD
Octreotide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.13e-05	0.000324	CcSEcCtD
Octreotide—Insomnia—Epirubicin—urinary bladder cancer	5.12e-05	0.000324	CcSEcCtD
Octreotide—Tachycardia—Doxorubicin—urinary bladder cancer	5.11e-05	0.000323	CcSEcCtD
Octreotide—Skin disorder—Doxorubicin—urinary bladder cancer	5.09e-05	0.000322	CcSEcCtD
Octreotide—Paraesthesia—Epirubicin—urinary bladder cancer	5.09e-05	0.000322	CcSEcCtD
Octreotide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.07e-05	0.00032	CcSEcCtD
Octreotide—Dyspnoea—Epirubicin—urinary bladder cancer	5.05e-05	0.000319	CcSEcCtD
Octreotide—SSTR1—G alpha (i) signalling events—CXCL8—urinary bladder cancer	5.04e-05	0.00656	CbGpPWpGaD
Octreotide—Somnolence—Epirubicin—urinary bladder cancer	5.03e-05	0.000318	CcSEcCtD
Octreotide—Anorexia—Doxorubicin—urinary bladder cancer	5e-05	0.000316	CcSEcCtD
Octreotide—Feeling abnormal—Methotrexate—urinary bladder cancer	4.99e-05	0.000315	CcSEcCtD
Octreotide—Dyspepsia—Epirubicin—urinary bladder cancer	4.99e-05	0.000315	CcSEcCtD
Octreotide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.95e-05	0.000313	CcSEcCtD
Octreotide—Decreased appetite—Epirubicin—urinary bladder cancer	4.92e-05	0.000311	CcSEcCtD
Octreotide—SSTR2—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	4.91e-05	0.00639	CbGpPWpGaD
Octreotide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.89e-05	0.000309	CcSEcCtD
Octreotide—SSTR2—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	4.89e-05	0.00636	CbGpPWpGaD
Octreotide—Fatigue—Epirubicin—urinary bladder cancer	4.88e-05	0.000309	CcSEcCtD
Octreotide—SSTR1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	4.87e-05	0.00634	CbGpPWpGaD
Octreotide—Pain—Epirubicin—urinary bladder cancer	4.84e-05	0.000306	CcSEcCtD
Octreotide—Constipation—Epirubicin—urinary bladder cancer	4.84e-05	0.000306	CcSEcCtD
Octreotide—Urticaria—Methotrexate—urinary bladder cancer	4.81e-05	0.000304	CcSEcCtD
Octreotide—Body temperature increased—Methotrexate—urinary bladder cancer	4.78e-05	0.000302	CcSEcCtD
Octreotide—Abdominal pain—Methotrexate—urinary bladder cancer	4.78e-05	0.000302	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.77e-05	0.000302	CcSEcCtD
Octreotide—Insomnia—Doxorubicin—urinary bladder cancer	4.74e-05	0.0003	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—HDAC4—urinary bladder cancer	4.71e-05	0.00614	CbGpPWpGaD
Octreotide—Paraesthesia—Doxorubicin—urinary bladder cancer	4.71e-05	0.000297	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—MYC—urinary bladder cancer	4.7e-05	0.00612	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—TP53—urinary bladder cancer	4.68e-05	0.00609	CbGpPWpGaD
Octreotide—Dyspnoea—Doxorubicin—urinary bladder cancer	4.67e-05	0.000295	CcSEcCtD
Octreotide—Feeling abnormal—Epirubicin—urinary bladder cancer	4.67e-05	0.000295	CcSEcCtD
Octreotide—Somnolence—Doxorubicin—urinary bladder cancer	4.66e-05	0.000295	CcSEcCtD
Octreotide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.63e-05	0.000293	CcSEcCtD
Octreotide—Dyspepsia—Doxorubicin—urinary bladder cancer	4.61e-05	0.000292	CcSEcCtD
Octreotide—Decreased appetite—Doxorubicin—urinary bladder cancer	4.56e-05	0.000288	CcSEcCtD
Octreotide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.52e-05	0.000286	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—HDAC4—urinary bladder cancer	4.52e-05	0.00588	CbGpPWpGaD
Octreotide—Fatigue—Doxorubicin—urinary bladder cancer	4.52e-05	0.000286	CcSEcCtD
Octreotide—Urticaria—Epirubicin—urinary bladder cancer	4.5e-05	0.000284	CcSEcCtD
Octreotide—Constipation—Doxorubicin—urinary bladder cancer	4.48e-05	0.000283	CcSEcCtD
Octreotide—Pain—Doxorubicin—urinary bladder cancer	4.48e-05	0.000283	CcSEcCtD
Octreotide—Abdominal pain—Epirubicin—urinary bladder cancer	4.48e-05	0.000283	CcSEcCtD
Octreotide—Body temperature increased—Epirubicin—urinary bladder cancer	4.48e-05	0.000283	CcSEcCtD
Octreotide—SSTR5—G alpha (i) signalling events—CXCL8—urinary bladder cancer	4.47e-05	0.00582	CbGpPWpGaD
Octreotide—Hypersensitivity—Methotrexate—urinary bladder cancer	4.46e-05	0.000282	CcSEcCtD
Octreotide—Asthenia—Methotrexate—urinary bladder cancer	4.34e-05	0.000275	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—KRAS—urinary bladder cancer	4.34e-05	0.00565	CbGpPWpGaD
Octreotide—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.32e-05	0.000273	CcSEcCtD
Octreotide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.29e-05	0.000271	CcSEcCtD
Octreotide—Pruritus—Methotrexate—urinary bladder cancer	4.28e-05	0.000271	CcSEcCtD
Octreotide—MPO—Selenium Micronutrient Network—TNF—urinary bladder cancer	4.22e-05	0.00549	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—CXCL8—urinary bladder cancer	4.2e-05	0.00547	CbGpPWpGaD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	4.18e-05	0.00544	CbGpPWpGaD
Octreotide—Hypersensitivity—Epirubicin—urinary bladder cancer	4.17e-05	0.000264	CcSEcCtD
Octreotide—Urticaria—Doxorubicin—urinary bladder cancer	4.16e-05	0.000263	CcSEcCtD
Octreotide—Abdominal pain—Doxorubicin—urinary bladder cancer	4.14e-05	0.000262	CcSEcCtD
Octreotide—Body temperature increased—Doxorubicin—urinary bladder cancer	4.14e-05	0.000262	CcSEcCtD
Octreotide—Diarrhoea—Methotrexate—urinary bladder cancer	4.14e-05	0.000262	CcSEcCtD
Octreotide—SSTR2—G alpha (i) signalling events—CXCL8—urinary bladder cancer	4.12e-05	0.00537	CbGpPWpGaD
Octreotide—Asthenia—Epirubicin—urinary bladder cancer	4.06e-05	0.000257	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—HDAC4—urinary bladder cancer	4.01e-05	0.00522	CbGpPWpGaD
Octreotide—Pruritus—Epirubicin—urinary bladder cancer	4.01e-05	0.000253	CcSEcCtD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	4.01e-05	0.00522	CbGpPWpGaD
Octreotide—Dizziness—Methotrexate—urinary bladder cancer	4e-05	0.000253	CcSEcCtD
Octreotide—SSTR2—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	3.98e-05	0.00519	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—GLI1—urinary bladder cancer	3.95e-05	0.00514	CbGpPWpGaD
Octreotide—Diarrhoea—Epirubicin—urinary bladder cancer	3.88e-05	0.000245	CcSEcCtD
Octreotide—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.86e-05	0.000244	CcSEcCtD
Octreotide—Vomiting—Methotrexate—urinary bladder cancer	3.85e-05	0.000243	CcSEcCtD
Octreotide—Rash—Methotrexate—urinary bladder cancer	3.82e-05	0.000241	CcSEcCtD
Octreotide—Dermatitis—Methotrexate—urinary bladder cancer	3.81e-05	0.000241	CcSEcCtD
Octreotide—Headache—Methotrexate—urinary bladder cancer	3.79e-05	0.00024	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—GLI1—urinary bladder cancer	3.79e-05	0.00493	CbGpPWpGaD
Octreotide—Asthenia—Doxorubicin—urinary bladder cancer	3.76e-05	0.000238	CcSEcCtD
Octreotide—Dizziness—Epirubicin—urinary bladder cancer	3.75e-05	0.000237	CcSEcCtD
Octreotide—Pruritus—Doxorubicin—urinary bladder cancer	3.71e-05	0.000234	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—HDAC4—urinary bladder cancer	3.7e-05	0.00482	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—HRAS—urinary bladder cancer	3.69e-05	0.0048	CbGpPWpGaD
Octreotide—Vomiting—Epirubicin—urinary bladder cancer	3.6e-05	0.000228	CcSEcCtD
Octreotide—Nausea—Methotrexate—urinary bladder cancer	3.59e-05	0.000227	CcSEcCtD
Octreotide—Diarrhoea—Doxorubicin—urinary bladder cancer	3.59e-05	0.000227	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—RBX1—urinary bladder cancer	3.57e-05	0.00465	CbGpPWpGaD
Octreotide—Rash—Epirubicin—urinary bladder cancer	3.57e-05	0.000226	CcSEcCtD
Octreotide—Dermatitis—Epirubicin—urinary bladder cancer	3.57e-05	0.000226	CcSEcCtD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.55e-05	0.00463	CbGpPWpGaD
Octreotide—Headache—Epirubicin—urinary bladder cancer	3.55e-05	0.000224	CcSEcCtD
Octreotide—Dizziness—Doxorubicin—urinary bladder cancer	3.47e-05	0.000219	CcSEcCtD
Octreotide—Nausea—Epirubicin—urinary bladder cancer	3.36e-05	0.000213	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—GLI1—urinary bladder cancer	3.36e-05	0.00437	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TSC1—urinary bladder cancer	3.36e-05	0.00437	CbGpPWpGaD
Octreotide—Vomiting—Doxorubicin—urinary bladder cancer	3.33e-05	0.000211	CcSEcCtD
Octreotide—Rash—Doxorubicin—urinary bladder cancer	3.3e-05	0.000209	CcSEcCtD
Octreotide—Dermatitis—Doxorubicin—urinary bladder cancer	3.3e-05	0.000209	CcSEcCtD
Octreotide—Headache—Doxorubicin—urinary bladder cancer	3.28e-05	0.000208	CcSEcCtD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.28e-05	0.00427	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—JAG1—urinary bladder cancer	3.2e-05	0.00416	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—CXCL8—urinary bladder cancer	3.18e-05	0.00414	CbGpPWpGaD
Octreotide—Nausea—Doxorubicin—urinary bladder cancer	3.11e-05	0.000197	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—GLI1—urinary bladder cancer	3.1e-05	0.00404	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—CXCL8—urinary bladder cancer	3.05e-05	0.00397	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—RBX1—urinary bladder cancer	2.71e-05	0.00352	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—CXCL8—urinary bladder cancer	2.71e-05	0.00352	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—RHOA—urinary bladder cancer	2.7e-05	0.00352	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—RBX1—urinary bladder cancer	2.6e-05	0.00338	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—S100B—urinary bladder cancer	2.59e-05	0.00337	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TSC1—urinary bladder cancer	2.55e-05	0.00331	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—CXCL8—urinary bladder cancer	2.5e-05	0.00325	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—RHOA—urinary bladder cancer	2.45e-05	0.0032	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TSC1—urinary bladder cancer	2.44e-05	0.00318	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—JAG1—urinary bladder cancer	2.42e-05	0.00315	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.37e-05	0.00309	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—NCOR1—urinary bladder cancer	2.33e-05	0.00303	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—JAG1—urinary bladder cancer	2.32e-05	0.00302	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—RBX1—urinary bladder cancer	2.3e-05	0.003	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—IL2—urinary bladder cancer	2.27e-05	0.00295	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TSC1—urinary bladder cancer	2.16e-05	0.00282	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—CXCL8—urinary bladder cancer	2.15e-05	0.00281	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—RBX1—urinary bladder cancer	2.12e-05	0.00277	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—JAG1—urinary bladder cancer	2.06e-05	0.00268	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—IL2—urinary bladder cancer	2.06e-05	0.00268	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TERT—urinary bladder cancer	2.05e-05	0.00267	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—RHOA—urinary bladder cancer	2.05e-05	0.00267	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TSC1—urinary bladder cancer	2e-05	0.0026	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.96e-05	0.00256	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—S100B—urinary bladder cancer	1.96e-05	0.00255	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—JAG1—urinary bladder cancer	1.9e-05	0.00248	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—FGFR3—urinary bladder cancer	1.88e-05	0.00245	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—S100B—urinary bladder cancer	1.88e-05	0.00245	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—RHOA—urinary bladder cancer	1.86e-05	0.00242	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—ESR1—urinary bladder cancer	1.83e-05	0.00238	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.8e-05	0.00234	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—RHOA—urinary bladder cancer	1.78e-05	0.00232	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—NCOR1—urinary bladder cancer	1.76e-05	0.0023	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—RHOA—urinary bladder cancer	1.74e-05	0.00227	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.72e-05	0.00224	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—IL2—urinary bladder cancer	1.72e-05	0.00224	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NCOR1—urinary bladder cancer	1.69e-05	0.0022	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—S100B—urinary bladder cancer	1.67e-05	0.00217	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—IL2—urinary bladder cancer	1.65e-05	0.00214	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—CXCL8—urinary bladder cancer	1.63e-05	0.00213	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—RHOA—urinary bladder cancer	1.61e-05	0.00209	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CREBBP—urinary bladder cancer	1.6e-05	0.00209	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—IGF1—urinary bladder cancer	1.58e-05	0.00206	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—RHOA—urinary bladder cancer	1.58e-05	0.00206	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—EGFR—urinary bladder cancer	1.58e-05	0.00205	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.57e-05	0.00204	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—IL2—urinary bladder cancer	1.56e-05	0.00203	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TERT—urinary bladder cancer	1.56e-05	0.00202	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—S100B—urinary bladder cancer	1.54e-05	0.002	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.53e-05	0.00199	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NCOR1—urinary bladder cancer	1.5e-05	0.00195	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—IL2—urinary bladder cancer	1.5e-05	0.00195	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TERT—urinary bladder cancer	1.49e-05	0.00194	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—KRAS—urinary bladder cancer	1.49e-05	0.00194	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—IL2—urinary bladder cancer	1.46e-05	0.0019	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—RHOA—urinary bladder cancer	1.46e-05	0.0019	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—RHOA—urinary bladder cancer	1.45e-05	0.00189	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—FGFR3—urinary bladder cancer	1.43e-05	0.00186	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.41e-05	0.00184	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—CXCL8—urinary bladder cancer	1.39e-05	0.00181	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—ESR1—urinary bladder cancer	1.39e-05	0.0018	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NCOR1—urinary bladder cancer	1.38e-05	0.0018	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—FGFR3—urinary bladder cancer	1.37e-05	0.00178	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—IL2—urinary bladder cancer	1.35e-05	0.00176	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—ERBB2—urinary bladder cancer	1.34e-05	0.00175	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—ESR1—urinary bladder cancer	1.33e-05	0.00173	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—IL2—urinary bladder cancer	1.33e-05	0.00173	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TERT—urinary bladder cancer	1.32e-05	0.00172	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—CXCL8—urinary bladder cancer	1.28e-05	0.00167	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CXCL8—urinary bladder cancer	1.27e-05	0.00166	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—HRAS—urinary bladder cancer	1.26e-05	0.00165	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—IL2—urinary bladder cancer	1.22e-05	0.00159	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TERT—urinary bladder cancer	1.22e-05	0.00159	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—IL2—urinary bladder cancer	1.22e-05	0.00158	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CREBBP—urinary bladder cancer	1.21e-05	0.00158	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—FGFR3—urinary bladder cancer	1.21e-05	0.00158	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IGF1—urinary bladder cancer	1.2e-05	0.00156	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—EGFR—urinary bladder cancer	1.19e-05	0.00155	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CCND1—urinary bladder cancer	1.19e-05	0.00154	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—ESR1—urinary bladder cancer	1.18e-05	0.00153	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CREBBP—urinary bladder cancer	1.16e-05	0.00152	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MMP9—urinary bladder cancer	1.15e-05	0.0015	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—IGF1—urinary bladder cancer	1.15e-05	0.0015	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CDKN1A—urinary bladder cancer	1.15e-05	0.00149	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PTEN—urinary bladder cancer	1.14e-05	0.00149	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—EGFR—urinary bladder cancer	1.14e-05	0.00149	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—KRAS—urinary bladder cancer	1.13e-05	0.00147	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—FGFR3—urinary bladder cancer	1.12e-05	0.00146	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—RHOA—urinary bladder cancer	1.1e-05	0.00143	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—EP300—urinary bladder cancer	1.09e-05	0.00142	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—ESR1—urinary bladder cancer	1.09e-05	0.00142	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—KRAS—urinary bladder cancer	1.08e-05	0.00141	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—SRC—urinary bladder cancer	1.06e-05	0.00138	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—RHOA—urinary bladder cancer	1.05e-05	0.00137	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CREBBP—urinary bladder cancer	1.03e-05	0.00134	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IGF1—urinary bladder cancer	1.02e-05	0.00133	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—ERBB2—urinary bladder cancer	1.02e-05	0.00132	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—EGFR—urinary bladder cancer	1.01e-05	0.00132	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—ERBB2—urinary bladder cancer	9.75e-06	0.00127	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CXCL8—urinary bladder cancer	9.65e-06	0.00126	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—KRAS—urinary bladder cancer	9.59e-06	0.00125	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—HRAS—urinary bladder cancer	9.59e-06	0.00125	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CREBBP—urinary bladder cancer	9.53e-06	0.00124	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MYC—urinary bladder cancer	9.51e-06	0.00124	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IGF1—urinary bladder cancer	9.41e-06	0.00123	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—EGFR—urinary bladder cancer	9.37e-06	0.00122	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—RHOA—urinary bladder cancer	9.34e-06	0.00122	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—EGFR—urinary bladder cancer	9.3e-06	0.00121	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CXCL8—urinary bladder cancer	9.25e-06	0.0012	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IL2—urinary bladder cancer	9.22e-06	0.0012	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—HRAS—urinary bladder cancer	9.19e-06	0.0012	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CCND1—urinary bladder cancer	8.99e-06	0.00117	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—KRAS—urinary bladder cancer	8.85e-06	0.00115	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—IL2—urinary bladder cancer	8.84e-06	0.00115	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—KRAS—urinary bladder cancer	8.79e-06	0.00114	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MMP9—urinary bladder cancer	8.73e-06	0.00114	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CDKN1A—urinary bladder cancer	8.69e-06	0.00113	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PTEN—urinary bladder cancer	8.68e-06	0.00113	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—ERBB2—urinary bladder cancer	8.65e-06	0.00113	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—RHOA—urinary bladder cancer	8.62e-06	0.00112	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CCND1—urinary bladder cancer	8.62e-06	0.00112	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MMP9—urinary bladder cancer	8.37e-06	0.00109	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.34e-06	0.00109	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PTEN—urinary bladder cancer	8.32e-06	0.00108	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EP300—urinary bladder cancer	8.27e-06	0.00108	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CXCL8—urinary bladder cancer	8.2e-06	0.00107	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—HRAS—urinary bladder cancer	8.15e-06	0.00106	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—SRC—urinary bladder cancer	8.05e-06	0.00105	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—ERBB2—urinary bladder cancer	7.98e-06	0.00104	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EP300—urinary bladder cancer	7.93e-06	0.00103	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IL2—urinary bladder cancer	7.84e-06	0.00102	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TP53—urinary bladder cancer	7.81e-06	0.00102	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—SRC—urinary bladder cancer	7.71e-06	0.001	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CCND1—urinary bladder cancer	7.64e-06	0.000995	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CXCL8—urinary bladder cancer	7.57e-06	0.000985	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—HRAS—urinary bladder cancer	7.52e-06	0.000979	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—HRAS—urinary bladder cancer	7.47e-06	0.000973	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MMP9—urinary bladder cancer	7.42e-06	0.000966	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CDKN1A—urinary bladder cancer	7.39e-06	0.000962	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PTEN—urinary bladder cancer	7.38e-06	0.00096	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IL2—urinary bladder cancer	7.23e-06	0.000942	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MYC—urinary bladder cancer	7.21e-06	0.000938	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CCND1—urinary bladder cancer	7.05e-06	0.000918	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EGFR—urinary bladder cancer	7.05e-06	0.000918	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EP300—urinary bladder cancer	7.03e-06	0.000916	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MYC—urinary bladder cancer	6.91e-06	0.0009	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MMP9—urinary bladder cancer	6.85e-06	0.000891	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—SRC—urinary bladder cancer	6.84e-06	0.00089	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.82e-06	0.000888	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PTEN—urinary bladder cancer	6.81e-06	0.000886	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EGFR—urinary bladder cancer	6.76e-06	0.00088	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—KRAS—urinary bladder cancer	6.66e-06	0.000867	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—EP300—urinary bladder cancer	6.49e-06	0.000845	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—KRAS—urinary bladder cancer	6.39e-06	0.000831	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—SRC—urinary bladder cancer	6.31e-06	0.000822	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MYC—urinary bladder cancer	6.13e-06	0.000798	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EGFR—urinary bladder cancer	6e-06	0.00078	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TP53—urinary bladder cancer	5.92e-06	0.000771	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TP53—urinary bladder cancer	5.68e-06	0.000739	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—KRAS—urinary bladder cancer	5.66e-06	0.000737	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—HRAS—urinary bladder cancer	5.66e-06	0.000737	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MYC—urinary bladder cancer	5.66e-06	0.000736	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—EGFR—urinary bladder cancer	5.53e-06	0.00072	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—HRAS—urinary bladder cancer	5.43e-06	0.000707	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—KRAS—urinary bladder cancer	5.23e-06	0.00068	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TP53—urinary bladder cancer	5.03e-06	0.000655	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—HRAS—urinary bladder cancer	4.81e-06	0.000627	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TP53—urinary bladder cancer	4.65e-06	0.000605	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—HRAS—urinary bladder cancer	4.44e-06	0.000578	CbGpPWpGaD
